Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Trial Profile

A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2019

At a glance

  • Drugs Niraparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NOVA
  • Sponsors TESARO
  • Most Recent Events

    • 07 Jun 2019 Primary endpoint (Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation (Non-gBRCA)) has not been met, according to the results published in the Journal of Clinical Oncology.
    • 07 Jun 2019 Primary endpoint (Progression-Free Survival (PFS) in Cohort With Germline BRCA Mutation (gBRCA)) has been met, according to the results published in the Journal of Clinical Oncology.
    • 07 Jun 2019 Safety and efficacy results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top